Eli Lilly has officially announced its acquisition of AtaiBeckley, a biotechnology company specializing in psychedelic treatments, for an initial $2.8 billion, with potential total costs reaching up to $3.8 billion. This strategic move is aimed at advancing therapies for treatment-resistant depression and other mental health conditions, amid increasing interest in psychedelic drugs as alternatives in mental health care. The acquisition is seen as a significant step for Lilly as it seeks to establish itself in the burgeoning psychedelics market, competing with major players in the industry. Shares of AtaiBeckley soared shortly after the deal was revealed, reflecting investor optimism about the future of psychedelics in therapeutic applications.